XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating Expenses:    
Research and development $ 1,519,633  
Research and development   $ (38,971)
General and administrative 1,636,557 1,053,505
Transaction costs 5,765,407 0
Change in fair value of contingent consideration (820,000) 0
Total operating expenses 8,101,597 1,014,534
Loss from operations (8,101,597) (1,014,534)
Other Expenses:    
Other expense, net (2,564) (4,678)
Loss on sales of NTN assets (9,598,173) 0
Total other expenses (9,600,737) (4,678)
Net loss attributable to common stockholders $ (17,702,334) $ (1,019,212)
Basic net loss per share attributable to common stockholders (in dollars per share) $ (0.64) $ (0.06)
Diluted net loss per share attributable to common stockholders (in dollars per share) $ (0.64) $ (0.06)
Basic weighted average number of shares outstanding (in shares) 27,799,415 17,501,813
Diluted weighted average number of shares outstanding (in shares) 27,799,415 17,501,813